S1322 |
Dexamethasone
|
Dexamethasone is a potent synthetic member of the glucocorticoid class of steroid drugs, and an interleukin receptor modulator that has anti-inflammatory and immunosuppressant effects. Dexamethasone induces autophagy and mitophagy. Dexamethasone is tested in hospitalized patients with COVID-19 and is found to have benefits for critically ill patients. |
-
Cell Host Microbe, 2024, S1931-3128(24)00005-2
-
Nat Commun, 2024, 15(1):7991
-
Nat Commun, 2024, 15(1):1176
|
|
A2012 |
Tocilizumab (anti-IL-6R)
|
Tocilizumab (anti-IL-6R) is a humanized monoclonal antibody that binds to the interleukin-6 receptor, MW: 148 KD. |
-
Nature, 2024, 10.1038/s41586-024-08031-6
-
Cell Rep Med, 2024, S2666-3791(24)00195-2
-
J Exp Clin Cancer Res, 2024, 43(1):277
|
|
S3124 |
Dexamethasone Acetate
|
Dexamethasone (NSC 39471,Dexamethasone 21-acetate) is a potent synthetic member of the glucocorticoid class of steroid drugs, and an interleukin receptor modulator that has anti-inflammatory and immunosuppressant effects. |
-
STAR Protoc, 2023, 4(2):102342
-
Exp Mol Med, 2022, 54(9):1450-1460
-
iScience, 2022, 25(12):105682
|
|
S4028 |
Dexamethasone Sodium Phosphate
|
Dexamethasone (Dexamethasone 21-phosphate disodium salt) is a potent synthetic member of the glucocorticoid class of steroid drugs, and an interleukin receptor modulator that has anti-inflammatory and immunosuppressant effects. |
-
Cancer Cell, 2024, 42(9):1507-1527.e11
-
Pharmaceutics, 2022, 14(2)400
-
Front Oncol, 2022, 12:888695
|
|
A2011 |
Sarilumab (anti-IL-6Rα)
|
Sarilumab (anti-IL-6Rα) is a fully human anti-IL-6Rα mAb that binds membrane-bound and soluble human IL-6Rα with high affinity, MW: 144.13 KD. |
-
Biomed Pharmacother, 2024, 173:116357
-
Small, 2023, e2203725.
-
Cancer Lett, 2022, 524:161-171
|
|
S8562 |
IRAK4-IN-2
|
IRAK4-IN-2 is a reversible kinase inhibitor that modulates IRAK4 function in both the toll-like receptor (TLR) and interleukin 1 receptor (IL-1R) signaling cascades. |
-
Cancer Lett, 2021, 503:75-90
-
Cancer Lett, 2021, 503:75-90
|
|
S5764 |
YM 90709
|
YM 90709 is a novel IL-5 inhibitor which selectively blocks the binding of IL-5 to the IL-5 receptor (IL-5R). |
|
|
A2424 |
Anti-IL-7Ra / CD127
|
Anti-IL-7Ra / CD127 is a monoclonal antibody against human IL-7Rα with therapeutic benefit against T-ALL (T-cell acute lymphoblastic leukemia). MW: 145.5 kD. |
|
|
A2427 |
Benralizumab (Anti-IL-5Ra/ CD125)
|
Benralizumab (Anti-IL-5Ra/ CD125) is an afucosylated, humanized monoclonal antibody against the alpha chain of the interleukin-5 receptor (IL-5Ra) with potential anti-asthmatic activity. MW: 145.5 kD. |
|
|
A2431 |
Talacotuzumab (Anti-IL-3Ra / CD123)
|
Talacotuzumab (Anti-IL-3Ra / CD123) is a humanized IgG1 monoclonal antibody against CD123 (Interleukin-3 receptor alpha chain or IL3RA) with potential antineoplastic activity. MW: 146.06 kD. |
|
|
A2433 |
Nemolizumab (Anti-IL-31Ra)
|
Nemolizumab (Anti-IL-31Ra) is a humanized monoclonal antibody, targeting IL-31Ra. It inhibits the binding of interleukin-31 (IL-31) to its receptor and subsequent signal transduction. Nemolizumab can used be in research of atopic dermatitis (AD). MW:145.5 KD. |
|
|
A2631 |
Anti-IL-3Ra / CD123 (SNG-CD123A)
|
Anti-IL-3Ra / CD123 (SNG-CD123A) is an antibody-drug conjugate targeting IL-3 alpha chain receptor (CD123). It is a potent antileukemic agent in treatment of acute myelogenous leukemia(AML). MW :146.14 KD. |
|
|
E3310 |
Brassica Juncea Seed Extract
|
Brassica juncea seed Extract is obtained from seeds of Brassica juncea L., which confers a protective/therapeutic effect against thioacetamide-induced acute liver failure in experimental animal models, by markedly downregulating the expression levels of TNF-α and IL-6, and reversing DNA genotoxicity. |
|
|
A2665 |
Anrukinzumab (Anti-IL-13)
|
Anrukinzumab (Anti-IL-13) is a humanized monoclonal antibody targeting IL-13. It reduces lung inflammation and can be used in studies of ulcerative colitis (UC) as well as asthma. MW :150 KD. |
|
|
A2666 |
Anti-IL-13Ra2 / CD213a2
|
Anti-IL-13Ra2 / CD213a2 is a humanized monoclonal antibody targeting IL-13Ra2. It exhibits potentcy against malignant gliomas (MG), head and neck tumors, ovarian cancer and kidney cancer. MW :150 KD. |
|
|
A2667 |
Imsidolimab (Anti-IL-1RL2 / IL-36R)
|
Imsidolimab (Anti-IL-1RL2 / IL-36R) is a high-affinity, humanized monoclonal antibody targeting IL-36R. It has potential application in generalized pustular psoriasis (GPP) and other inflammatory skin diseases. MW :150 KD. |
|
|
A2668 |
Etokimab (Anti-IL-33)
|
Etokimab (Anti-IL-33) is a humanized monoclonal antibody that targets IL-33. It can be used for the research of atopic dermatitis. MW :146.56 KD. |
|
|
A2669 |
Lusvertikimab (Anti-IL-7Ra / CD127)
|
Lusvertikimab (Anti-IL-7Ra / CD127) is a humanized monoclonal antibody targeting IL7R. It has anti-leukemic efficacy and has the potential for B cell precursor acute lymphoblastic leukemia (BCP-ALL) research. MW :145.64 KD. |
|
|
A2107 |
Anti-mouse CD25 (IL-2Rα)-InVivo
|
The PC-61.5.3 monoclonal antibody reacts with mouse IL-2Rα also known as CD25, Ly-43, p55, or Tac.The PC-61.5.3 antibody has been shown to inhibit the binding of IL-2 to both the low and high affinity IL-2 receptor forms. Additionally, the PC-61.5.3 antibody is commonly used to deplete CD4+FoxP3+ T regulatory cells in vivo. |
|
|
A2109 |
Anti-mouse IL-4-InVivo
|
The 11B11 monoclonal antibody reacts with mouse IL-4 (interleukin-4) which is a multifunctional 14 kDa cytokine.The 11B11 monoclonal antibody has been shown to neutralize the bioactivity of natural or recombinant IL-4. |
|
|
S4028 |
Dexamethasone Sodium Phosphate
|
Dexamethasone (Dexamethasone 21-phosphate disodium salt) is a potent synthetic member of the glucocorticoid class of steroid drugs, and an interleukin receptor modulator that has anti-inflammatory and immunosuppressant effects. |
- Cancer Cell, 2024, 42(9):1507-1527.e11
- Pharmaceutics, 2022, 14(2)400
- Front Oncol, 2022, 12:888695
|
|
S8562 |
IRAK4-IN-2
|
IRAK4-IN-2 is a reversible kinase inhibitor that modulates IRAK4 function in both the toll-like receptor (TLR) and interleukin 1 receptor (IL-1R) signaling cascades. |
- Cancer Lett, 2021, 503:75-90
- Cancer Lett, 2021, 503:75-90
|
|
S5764 |
YM 90709
|
YM 90709 is a novel IL-5 inhibitor which selectively blocks the binding of IL-5 to the IL-5 receptor (IL-5R). |
|
|
E3310 |
Brassica Juncea Seed Extract
|
Brassica juncea seed Extract is obtained from seeds of Brassica juncea L., which confers a protective/therapeutic effect against thioacetamide-induced acute liver failure in experimental animal models, by markedly downregulating the expression levels of TNF-α and IL-6, and reversing DNA genotoxicity. |
|
|
A2012 |
Tocilizumab (anti-IL-6R)
|
Tocilizumab (anti-IL-6R) is a humanized monoclonal antibody that binds to the interleukin-6 receptor, MW: 148 KD. |
- Nature, 2024, 10.1038/s41586-024-08031-6
- Cell Rep Med, 2024, S2666-3791(24)00195-2
- J Exp Clin Cancer Res, 2024, 43(1):277
|
|
A2011 |
Sarilumab (anti-IL-6Rα)
|
Sarilumab (anti-IL-6Rα) is a fully human anti-IL-6Rα mAb that binds membrane-bound and soluble human IL-6Rα with high affinity, MW: 144.13 KD. |
- Biomed Pharmacother, 2024, 173:116357
- Small, 2023, e2203725.
- Cancer Lett, 2022, 524:161-171
|
|
A2424 |
Anti-IL-7Ra / CD127
|
Anti-IL-7Ra / CD127 is a monoclonal antibody against human IL-7Rα with therapeutic benefit against T-ALL (T-cell acute lymphoblastic leukemia). MW: 145.5 kD. |
|
|
A2427 |
Benralizumab (Anti-IL-5Ra/ CD125)
|
Benralizumab (Anti-IL-5Ra/ CD125) is an afucosylated, humanized monoclonal antibody against the alpha chain of the interleukin-5 receptor (IL-5Ra) with potential anti-asthmatic activity. MW: 145.5 kD. |
|
|
A2431 |
Talacotuzumab (Anti-IL-3Ra / CD123)
|
Talacotuzumab (Anti-IL-3Ra / CD123) is a humanized IgG1 monoclonal antibody against CD123 (Interleukin-3 receptor alpha chain or IL3RA) with potential antineoplastic activity. MW: 146.06 kD. |
|
|
A2433 |
Nemolizumab (Anti-IL-31Ra)
|
Nemolizumab (Anti-IL-31Ra) is a humanized monoclonal antibody, targeting IL-31Ra. It inhibits the binding of interleukin-31 (IL-31) to its receptor and subsequent signal transduction. Nemolizumab can used be in research of atopic dermatitis (AD). MW:145.5 KD. |
|
|
A2631 |
Anti-IL-3Ra / CD123 (SNG-CD123A)
|
Anti-IL-3Ra / CD123 (SNG-CD123A) is an antibody-drug conjugate targeting IL-3 alpha chain receptor (CD123). It is a potent antileukemic agent in treatment of acute myelogenous leukemia(AML). MW :146.14 KD. |
|
|
A2665 |
Anrukinzumab (Anti-IL-13)
|
Anrukinzumab (Anti-IL-13) is a humanized monoclonal antibody targeting IL-13. It reduces lung inflammation and can be used in studies of ulcerative colitis (UC) as well as asthma. MW :150 KD. |
|
|
A2666 |
Anti-IL-13Ra2 / CD213a2
|
Anti-IL-13Ra2 / CD213a2 is a humanized monoclonal antibody targeting IL-13Ra2. It exhibits potentcy against malignant gliomas (MG), head and neck tumors, ovarian cancer and kidney cancer. MW :150 KD. |
|
|
A2667 |
Imsidolimab (Anti-IL-1RL2 / IL-36R)
|
Imsidolimab (Anti-IL-1RL2 / IL-36R) is a high-affinity, humanized monoclonal antibody targeting IL-36R. It has potential application in generalized pustular psoriasis (GPP) and other inflammatory skin diseases. MW :150 KD. |
|
|
A2668 |
Etokimab (Anti-IL-33)
|
Etokimab (Anti-IL-33) is a humanized monoclonal antibody that targets IL-33. It can be used for the research of atopic dermatitis. MW :146.56 KD. |
|
|
A2669 |
Lusvertikimab (Anti-IL-7Ra / CD127)
|
Lusvertikimab (Anti-IL-7Ra / CD127) is a humanized monoclonal antibody targeting IL7R. It has anti-leukemic efficacy and has the potential for B cell precursor acute lymphoblastic leukemia (BCP-ALL) research. MW :145.64 KD. |
|
|
A2107 |
Anti-mouse CD25 (IL-2Rα)-InVivo
|
The PC-61.5.3 monoclonal antibody reacts with mouse IL-2Rα also known as CD25, Ly-43, p55, or Tac.The PC-61.5.3 antibody has been shown to inhibit the binding of IL-2 to both the low and high affinity IL-2 receptor forms. Additionally, the PC-61.5.3 antibody is commonly used to deplete CD4+FoxP3+ T regulatory cells in vivo. |
|
|
A2109 |
Anti-mouse IL-4-InVivo
|
The 11B11 monoclonal antibody reacts with mouse IL-4 (interleukin-4) which is a multifunctional 14 kDa cytokine.The 11B11 monoclonal antibody has been shown to neutralize the bioactivity of natural or recombinant IL-4. |
|
|